GlassScriptPhysician profile
Michael Joseph Larkin
NPI 1639147788
$6,700.18
in general payments reported to CMS, 2019-2025
25 companies · $863 in 2025
The $863 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,764 · 2020: $590 · 2021: $846 · 2022: $756 · 2023: $855 · 2024: $1,026 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,744.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,187.74 | 2019-2025 | Agilis Hispro, Gallant, Jot Dx |
| Boston Scientific Corporation | $1,525.22 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Janssen Pharmaceuticals, INC | $398.45 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $248.06 | 2021-2025 | Camzyos, Eliquis |
| Medtronic Vascular, INC. | $182.25 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $151.05 | 2023-2025 | Lifevest |
| Abiomed | $119.01 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $110.42 | 2021-2024 | |
| Medtronic, INC. | $108.90 | 2023-2024 | Linq II, Reveal Linq, Mycarelink |
| Sanofi-Aventis U.S. LLC | $96.12 | 2021-2024 | |
| Novo Nordisk INC | $78.53 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $73.07 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $60.49 | 2023-2025 | Onpattro |
| Shockwave Medical, INC | $56.75 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $37.92 | 2023 | Inpefa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $34.94 | 2024-2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $32.37 | 2021-2025 | Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $32.13 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $29.90 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $28.51 | 2021-2023 | Brilinta |
| Amgen INC. | $27.34 | 2022 | |
| Atricure, INC. | $25.47 | 2022 | |
| Daiichi Sankyo INC. | $24.15 | 2023 | Injectafer |
| Kiniksa Pharmaceuticals International, Plc | $18.48 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $12.91 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Larkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.